Show simple item record

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

dc.contributor.authorDirix, Luc Y.en_US
dc.contributor.authorEynden, Gert G.en_US
dc.contributor.authorLaere, Steven J.en_US
dc.contributor.authorAuwera, Ilseen_US
dc.contributor.authorVandenberghe, Melanieen_US
dc.contributor.authorDam, Peteren_US
dc.contributor.authorMarck, Eric A.en_US
dc.contributor.authorGolen, Kenneth L.en_US
dc.contributor.authorVermeulen, Peter B.en_US
dc.date.accessioned2006-09-11T14:28:57Z
dc.date.available2006-09-11T14:28:57Z
dc.date.issued2006-02en_US
dc.identifier.citationLaere, Steven J.; Eynden, Gert G.; Auwera, Ilse; Vandenberghe, Melanie; Dam, Peter; Marck, Eric A.; Golen, Kenneth L.; Vermeulen, Peter B.; Dirix, Luc Y.; (2006). "Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling." Breast Cancer Research and Treatment 95(3): 243-255. <http://hdl.handle.net/2027.42/44236>en_US
dc.identifier.issn0167-6806en_US
dc.identifier.issn1573-7217en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/44236
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16261404&dopt=citationen_US
dc.description.abstractInflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer with high metastatic potential. Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant metastases. In a previous study, we demonstrated that IBC is a distinct form of breast cancer in comparison with non-IBC. The aim of this study was to investigate the presence of the different molecular subtypes in our data set of 16 IBC and 18 non-IBC specimen. Therefore, we selected an ‘intrinsic gene set’ of 144 genes, present on our cDNA chips and common to the ‘intrinsic gene set’ described by Sorlie et al. [PNAS, 2003]. This set of genes was tested for performance in the Norway/Stanford data set by unsupervised hierarchical clustering. Expression centroids were then calculated for the core members of each of the five subclasses in the Norway/Stanford data set and used to classify our own specimens by calculating Spearman correlations between each sample and each centroid. We identified the same cell-of-origin subtypes in IBC as those already described in non-IBC. The classification was in good agreement with immunohistochemical data for estrogen receptor protein expression and cytokeratin 5/6 protein expression. Confirmation was done by an alternative unsupervised hierarchical clustering method. The robustness of this classification was assessed by an unsupervised hierarchical clustering with an alternative gene set of 141 genes related to the cell-of-origin subtypes, selected using a discriminating score and iterative random permutation testing. The contribution of the different cell-of-origin subtypes to the IBC phenotype was investigated by principal component analysis. Generally, the combined ErbB2-overexpressing and basal-like cluster was more expressed in IBC compared to non-IBC, whereas the combined luminal A, luminal B and normal-like cluster was more pronounced in non-IBC compared to IBC. The presence of the same molecular cell-of-origin subtypes in IBC as in non-IBC does not exclude the specific molecular nature of IBC, since gene lists that characterize IBC and non-IBC are entirely different from gene lists that define the different cell-of-origin subtypes, as evidenced by principal component analysis.en_US
dc.format.extent724171 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Springer Science+Business Media, Inc.en_US
dc.subject.otherGene-expression Profilingen_US
dc.subject.otherCell-of-Origin Subtypesen_US
dc.subject.otherImflammatory Breast Canceren_US
dc.subject.otherMicroarrayen_US
dc.titleIdentification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profilingen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbsecondlevelOphthalmologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology and Oncology, The␣University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium, ; Department of Pathology, AZ Sint-Augustinus, Oosterveldlaan 24, B2610, Wilrijk, Belgium,en_US
dc.contributor.affiliationotherTranslational Cancer Research Group, Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid16261404en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/44236/1/10549_2005_Article_9015.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s10549-005-9015-9en_US
dc.identifier.sourceBreast Cancer Research and Treatmenten_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.